New therapy for advanced breast cancer patients
Share this @internewscast.com


The National Institute for Health and Care Excellence has overturned its draft rejection of Keytruda (pembrolizumab) and has said women can take the immunotherapy drug alongside chemotherapy.

The drug is for women with incurable secondary triple negative breast cancer. It aims to slow disease progression – buying patients extra time.

Baroness Delyth Morgan, chief executive of Breast Cancer Now, said it was “absolutely fantastic news for around 100 patients” every year with the disease.

She added: “Following its worrying provisional rejection by Nice earlier this year, the reversal of this decision now brings hope to eligible women.

“It could bring precious additional time before their disease progresses, and more months to live and spend time with loved ones and doing what matters most to them.”



Share this @internewscast.com
You May Also Like

Monkeypox latest: Symptoms can take ‘3 weeks’ to appear – signs to spot

How monkeypox is spread The UKHSA shared three main ways the virus…

Dementia: Pseudo pili torti may coincide with brain decline

Advancements in medicine have seen the number of elderly people increase year…

Cancer: Research has found a link to vitamin D deficiency

Carcinogenesis process by which normal cells are transformed into cancer cells. The…

Sam Faiers reveals she feels no pressure to ‘snap back’ to her pre-baby weight

‘I’m not ready to wear a bikini!’ Sam Faiers reveals she feels…

Canada to throw out 13.6 million doses of AstraZeneca COVID-19 vaccine

Ottawa — Canada is going to throw out about 13.6 million doses of…

Speed Up Belly Fat Loss in After 40 With These Proven Tips — Eat This Not That

Weight gain is a common problem that can happen as we age…

How to live longer: Loss of smell associated with an increased risk of death

A study published in May surveyed 616,318 people in the United States…

Covid: Symptoms include runny nose in UK as cases soar

Commenting on the rise, Professor Spector said: “Our ZOE Health Study data…